These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 10566048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tedisamil. KC 8857.
    Drugs R D; 1999 Apr; 1(4):327-30. PubMed ID: 10566055
    [No Abstract] [Full Text] [Related]

  • 5. E 4031.
    Drugs R D; 1999 Apr; 1(4):312-6. PubMed ID: 10566051
    [No Abstract] [Full Text] [Related]

  • 6. Azimilide.
    Clemett D, Markham A.
    Drugs; 2000 Feb; 59(2):271-7; discussion 278-9. PubMed ID: 10730550
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sematilide. CK 1752, CK 1752A, ZK 110516.
    Drugs R D; 1999 Apr; 1(4):322-6. PubMed ID: 10566054
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Diprafenone.
    Drugs R D; 1999 Apr; 1(4):301-3. PubMed ID: 10566049
    [No Abstract] [Full Text] [Related]

  • 11. Landiolol. ONO 1011.
    Drugs R D; 1999 Apr; 1(4):317-8. PubMed ID: 10566052
    [No Abstract] [Full Text] [Related]

  • 12. Azimilide dihydrochloride, a novel antiarrhythmic agent.
    Karam R, Marcello S, Brooks RR, Corey AE, Moore A.
    Am J Cardiol; 1998 Mar 19; 81(6A):40D-46D. PubMed ID: 9537222
    [Abstract] [Full Text] [Related]

  • 13. Otenzepad. AFDX 116.
    Drugs R D; 1999 Apr 19; 1(4):319-21. PubMed ID: 10566053
    [No Abstract] [Full Text] [Related]

  • 14. Newer antiarrhythmic drugs.
    Gupta AK, Maheshwari A, Thakur RK, Lokhandwala YY.
    Indian Heart J; 2001 Apr 19; 53(3):354-60. PubMed ID: 11516042
    [No Abstract] [Full Text] [Related]

  • 15. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
    Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, Karam R, Sonnenblick EH, Brum JM, AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators.
    Circulation; 2004 Mar 02; 109(8):990-6. PubMed ID: 14967728
    [Abstract] [Full Text] [Related]

  • 16. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs.
    Qi XQ, Newman D, Dorian P.
    J Cardiovasc Pharmacol; 1999 Dec 02; 34(6):898-903. PubMed ID: 10598136
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
    Brooks RR, Carpenter JF, Miller KE, Maynard AE.
    Proc Soc Exp Biol Med; 1996 May 02; 212(1):84-93. PubMed ID: 8618956
    [Abstract] [Full Text] [Related]

  • 18. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
    Drexler AP, Micklas JM, Brooks RR.
    J Cardiovasc Pharmacol; 1996 Dec 02; 28(6):848-55. PubMed ID: 8961084
    [Abstract] [Full Text] [Related]

  • 19. Azimilide for atrial fibrillation: clinical trial results and implications.
    Pritchett EL, Marcello SR.
    Card Electrophysiol Rev; 2003 Sep 02; 7(3):215-9. PubMed ID: 14739716
    [Abstract] [Full Text] [Related]

  • 20. Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.
    Reiffel JA.
    J Cardiovasc Pharmacol Ther; 2001 Oct 02; 6(4):333-9. PubMed ID: 11907635
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.